nodes	percent_of_prediction	percent_of_DWPC	metapath
Trametinib—MAP2K2—Sunitinib—pancreatic cancer	0.289	0.434	CbGbCtD
Trametinib—MAP2K1—Sunitinib—pancreatic cancer	0.289	0.434	CbGbCtD
Trametinib—CYP2C8—Tamoxifen—pancreatic cancer	0.0207	0.0311	CbGbCtD
Trametinib—CYP2C8—Erlotinib—pancreatic cancer	0.0176	0.0264	CbGbCtD
Trametinib—CYP2C8—Fluorouracil—pancreatic cancer	0.0153	0.0229	CbGbCtD
Trametinib—CYP3A4—Tamoxifen—pancreatic cancer	0.0084	0.0126	CbGbCtD
Trametinib—CYP3A4—Erlotinib—pancreatic cancer	0.00714	0.0107	CbGbCtD
Trametinib—CYP3A4—Irinotecan—pancreatic cancer	0.00645	0.00967	CbGbCtD
Trametinib—CYP3A4—Docetaxel—pancreatic cancer	0.00473	0.00709	CbGbCtD
Trametinib—CYP3A4—Sunitinib—pancreatic cancer	0.00471	0.00706	CbGbCtD
Trametinib—CYP3A4—Doxorubicin—pancreatic cancer	0.00352	0.00528	CbGbCtD
Trametinib—Nervous system disorder—Fluorouracil—pancreatic cancer	0.000128	0.000728	CcSEcCtD
Trametinib—Thrombocytopenia—Fluorouracil—pancreatic cancer	0.000128	0.000727	CcSEcCtD
Trametinib—Dizziness—Tamoxifen—pancreatic cancer	0.000128	0.000727	CcSEcCtD
Trametinib—Dizziness—Erlotinib—pancreatic cancer	0.000126	0.000719	CcSEcCtD
Trametinib—Eye disorder—Docetaxel—pancreatic cancer	0.000124	0.000705	CcSEcCtD
Trametinib—Insomnia—Irinotecan—pancreatic cancer	0.000123	0.000701	CcSEcCtD
Trametinib—Cardiac disorder—Docetaxel—pancreatic cancer	0.000123	0.0007	CcSEcCtD
Trametinib—Vomiting—Tamoxifen—pancreatic cancer	0.000123	0.000699	CcSEcCtD
Trametinib—Rash—Tamoxifen—pancreatic cancer	0.000122	0.000693	CcSEcCtD
Trametinib—Dermatitis—Tamoxifen—pancreatic cancer	0.000122	0.000692	CcSEcCtD
Trametinib—Vomiting—Erlotinib—pancreatic cancer	0.000122	0.000691	CcSEcCtD
Trametinib—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000121	0.000689	CcSEcCtD
Trametinib—Headache—Tamoxifen—pancreatic cancer	0.000121	0.000688	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000121	0.000688	CcSEcCtD
Trametinib—Rash—Erlotinib—pancreatic cancer	0.000121	0.000686	CcSEcCtD
Trametinib—Dermatitis—Erlotinib—pancreatic cancer	0.00012	0.000685	CcSEcCtD
Trametinib—Angiopathy—Docetaxel—pancreatic cancer	0.00012	0.000684	CcSEcCtD
Trametinib—Dehydration—Epirubicin—pancreatic cancer	0.00012	0.000684	CcSEcCtD
Trametinib—Hyponatraemia—Doxorubicin—pancreatic cancer	0.00012	0.000683	CcSEcCtD
Trametinib—Insomnia—Gemcitabine—pancreatic cancer	0.00012	0.000683	CcSEcCtD
Trametinib—Headache—Erlotinib—pancreatic cancer	0.00012	0.000681	CcSEcCtD
Trametinib—Pain in extremity—Doxorubicin—pancreatic cancer	0.00012	0.000681	CcSEcCtD
Trametinib—Mediastinal disorder—Docetaxel—pancreatic cancer	0.00012	0.00068	CcSEcCtD
Trametinib—Chills—Docetaxel—pancreatic cancer	0.000119	0.000677	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000119	0.000677	CcSEcCtD
Trametinib—Asthenia—Sunitinib—pancreatic cancer	0.000119	0.000675	CcSEcCtD
Trametinib—Dry skin—Epirubicin—pancreatic cancer	0.000119	0.000674	CcSEcCtD
Trametinib—Decreased appetite—Irinotecan—pancreatic cancer	0.000119	0.000674	CcSEcCtD
Trametinib—Arrhythmia—Docetaxel—pancreatic cancer	0.000119	0.000674	CcSEcCtD
Trametinib—Abdominal pain upper—Epirubicin—pancreatic cancer	0.000118	0.000672	CcSEcCtD
Trametinib—Insomnia—Fluorouracil—pancreatic cancer	0.000118	0.000672	CcSEcCtD
Trametinib—Hypokalaemia—Epirubicin—pancreatic cancer	0.000118	0.000669	CcSEcCtD
Trametinib—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000118	0.000669	CcSEcCtD
Trametinib—Fatigue—Irinotecan—pancreatic cancer	0.000118	0.000668	CcSEcCtD
Trametinib—Pruritus—Sunitinib—pancreatic cancer	0.000117	0.000666	CcSEcCtD
Trametinib—Constipation—Irinotecan—pancreatic cancer	0.000117	0.000663	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	0.000116	0.000662	CcSEcCtD
Trametinib—Mental disorder—Docetaxel—pancreatic cancer	0.000116	0.000661	CcSEcCtD
Trametinib—Erythema—Docetaxel—pancreatic cancer	0.000116	0.000657	CcSEcCtD
Trametinib—Malnutrition—Docetaxel—pancreatic cancer	0.000116	0.000657	CcSEcCtD
Trametinib—Decreased appetite—Gemcitabine—pancreatic cancer	0.000115	0.000657	CcSEcCtD
Trametinib—Nausea—Tamoxifen—pancreatic cancer	0.000115	0.000653	CcSEcCtD
Trametinib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000115	0.000652	CcSEcCtD
Trametinib—Fatigue—Gemcitabine—pancreatic cancer	0.000115	0.000651	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	0.000114	0.000649	CcSEcCtD
Trametinib—Constipation—Gemcitabine—pancreatic cancer	0.000114	0.000646	CcSEcCtD
Trametinib—Nausea—Erlotinib—pancreatic cancer	0.000114	0.000646	CcSEcCtD
Trametinib—Decreased appetite—Fluorouracil—pancreatic cancer	0.000114	0.000646	CcSEcCtD
Trametinib—Diarrhoea—Sunitinib—pancreatic cancer	0.000113	0.000644	CcSEcCtD
Trametinib—Dysgeusia—Docetaxel—pancreatic cancer	0.000113	0.000643	CcSEcCtD
Trametinib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000113	0.000641	CcSEcCtD
Trametinib—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000112	0.000638	CcSEcCtD
Trametinib—Back pain—Docetaxel—pancreatic cancer	0.000112	0.000635	CcSEcCtD
Trametinib—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000112	0.000634	CcSEcCtD
Trametinib—Dehydration—Doxorubicin—pancreatic cancer	0.000111	0.000633	CcSEcCtD
Trametinib—Muscle spasms—Docetaxel—pancreatic cancer	0.000111	0.000631	CcSEcCtD
Trametinib—Dry skin—Doxorubicin—pancreatic cancer	0.00011	0.000624	CcSEcCtD
Trametinib—Pancreatitis—Epirubicin—pancreatic cancer	0.00011	0.000623	CcSEcCtD
Trametinib—Dizziness—Sunitinib—pancreatic cancer	0.000109	0.000622	CcSEcCtD
Trametinib—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000109	0.000622	CcSEcCtD
Trametinib—Hypokalaemia—Doxorubicin—pancreatic cancer	0.000109	0.000619	CcSEcCtD
Trametinib—Abdominal pain—Irinotecan—pancreatic cancer	0.000108	0.000613	CcSEcCtD
Trametinib—Body temperature increased—Irinotecan—pancreatic cancer	0.000108	0.000613	CcSEcCtD
Trametinib—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000108	0.000613	CcSEcCtD
Trametinib—Anaemia—Docetaxel—pancreatic cancer	0.000107	0.000607	CcSEcCtD
Trametinib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000106	0.0006	CcSEcCtD
Trametinib—Vomiting—Sunitinib—pancreatic cancer	0.000105	0.000598	CcSEcCtD
Trametinib—Body temperature increased—Gemcitabine—pancreatic cancer	0.000105	0.000597	CcSEcCtD
Trametinib—Neutropenia—Epirubicin—pancreatic cancer	0.000105	0.000594	CcSEcCtD
Trametinib—Rash—Sunitinib—pancreatic cancer	0.000104	0.000594	CcSEcCtD
Trametinib—Dermatitis—Sunitinib—pancreatic cancer	0.000104	0.000593	CcSEcCtD
Trametinib—Headache—Sunitinib—pancreatic cancer	0.000104	0.00059	CcSEcCtD
Trametinib—Leukopenia—Docetaxel—pancreatic cancer	0.000103	0.000588	CcSEcCtD
Trametinib—Body temperature increased—Fluorouracil—pancreatic cancer	0.000103	0.000587	CcSEcCtD
Trametinib—Pancreatitis—Doxorubicin—pancreatic cancer	0.000101	0.000577	CcSEcCtD
Trametinib—Hyperglycaemia—Epirubicin—pancreatic cancer	0.000101	0.000573	CcSEcCtD
Trametinib—Cough—Docetaxel—pancreatic cancer	0.000101	0.000573	CcSEcCtD
Trametinib—Hypertension—Docetaxel—pancreatic cancer	9.97e-05	0.000567	CcSEcCtD
Trametinib—Infestation—Epirubicin—pancreatic cancer	9.97e-05	0.000567	CcSEcCtD
Trametinib—Infestation NOS—Epirubicin—pancreatic cancer	9.97e-05	0.000567	CcSEcCtD
Trametinib—Myalgia—Docetaxel—pancreatic cancer	9.83e-05	0.000559	CcSEcCtD
Trametinib—Arthralgia—Docetaxel—pancreatic cancer	9.83e-05	0.000559	CcSEcCtD
Trametinib—Nausea—Sunitinib—pancreatic cancer	9.83e-05	0.000559	CcSEcCtD
Trametinib—Renal failure—Epirubicin—pancreatic cancer	9.8e-05	0.000557	CcSEcCtD
Trametinib—Asthenia—Irinotecan—pancreatic cancer	9.78e-05	0.000556	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	9.77e-05	0.000555	CcSEcCtD
Trametinib—Stomatitis—Epirubicin—pancreatic cancer	9.72e-05	0.000553	CcSEcCtD
Trametinib—Urinary tract infection—Epirubicin—pancreatic cancer	9.69e-05	0.000551	CcSEcCtD
Trametinib—Neutropenia—Doxorubicin—pancreatic cancer	9.67e-05	0.00055	CcSEcCtD
Trametinib—Dry mouth—Docetaxel—pancreatic cancer	9.62e-05	0.000547	CcSEcCtD
Trametinib—Asthenia—Gemcitabine—pancreatic cancer	9.53e-05	0.000542	CcSEcCtD
Trametinib—Haematuria—Epirubicin—pancreatic cancer	9.51e-05	0.00054	CcSEcCtD
Trametinib—Oedema—Docetaxel—pancreatic cancer	9.43e-05	0.000536	CcSEcCtD
Trametinib—Epistaxis—Epirubicin—pancreatic cancer	9.4e-05	0.000535	CcSEcCtD
Trametinib—Pruritus—Gemcitabine—pancreatic cancer	9.4e-05	0.000534	CcSEcCtD
Trametinib—Infection—Docetaxel—pancreatic cancer	9.37e-05	0.000532	CcSEcCtD
Trametinib—Hyperglycaemia—Doxorubicin—pancreatic cancer	9.33e-05	0.000531	CcSEcCtD
Trametinib—Diarrhoea—Irinotecan—pancreatic cancer	9.33e-05	0.000531	CcSEcCtD
Trametinib—Nervous system disorder—Docetaxel—pancreatic cancer	9.24e-05	0.000526	CcSEcCtD
Trametinib—Pruritus—Fluorouracil—pancreatic cancer	9.24e-05	0.000525	CcSEcCtD
Trametinib—Thrombocytopenia—Docetaxel—pancreatic cancer	9.23e-05	0.000525	CcSEcCtD
Trametinib—Infestation NOS—Doxorubicin—pancreatic cancer	9.22e-05	0.000524	CcSEcCtD
Trametinib—Infestation—Doxorubicin—pancreatic cancer	9.22e-05	0.000524	CcSEcCtD
Trametinib—Skin disorder—Docetaxel—pancreatic cancer	9.16e-05	0.000521	CcSEcCtD
Trametinib—Bradycardia—Epirubicin—pancreatic cancer	9.11e-05	0.000518	CcSEcCtD
Trametinib—Diarrhoea—Gemcitabine—pancreatic cancer	9.09e-05	0.000517	CcSEcCtD
Trametinib—Renal failure—Doxorubicin—pancreatic cancer	9.07e-05	0.000516	CcSEcCtD
Trametinib—Dizziness—Irinotecan—pancreatic cancer	9.02e-05	0.000513	CcSEcCtD
Trametinib—Haemoglobin—Epirubicin—pancreatic cancer	8.99e-05	0.000511	CcSEcCtD
Trametinib—Stomatitis—Doxorubicin—pancreatic cancer	8.99e-05	0.000511	CcSEcCtD
Trametinib—Urinary tract infection—Doxorubicin—pancreatic cancer	8.97e-05	0.00051	CcSEcCtD
Trametinib—Haemorrhage—Epirubicin—pancreatic cancer	8.95e-05	0.000509	CcSEcCtD
Trametinib—Diarrhoea—Fluorouracil—pancreatic cancer	8.94e-05	0.000508	CcSEcCtD
Trametinib—Urinary tract disorder—Epirubicin—pancreatic cancer	8.84e-05	0.000503	CcSEcCtD
Trametinib—Oedema peripheral—Epirubicin—pancreatic cancer	8.82e-05	0.000501	CcSEcCtD
Trametinib—Haematuria—Doxorubicin—pancreatic cancer	8.8e-05	0.0005	CcSEcCtD
Trametinib—Connective tissue disorder—Epirubicin—pancreatic cancer	8.79e-05	0.0005	CcSEcCtD
Trametinib—Urethral disorder—Epirubicin—pancreatic cancer	8.77e-05	0.000499	CcSEcCtD
Trametinib—Epistaxis—Doxorubicin—pancreatic cancer	8.7e-05	0.000495	CcSEcCtD
Trametinib—Vomiting—Irinotecan—pancreatic cancer	8.67e-05	0.000493	CcSEcCtD
Trametinib—Dizziness—Fluorouracil—pancreatic cancer	8.64e-05	0.000491	CcSEcCtD
Trametinib—Rash—Irinotecan—pancreatic cancer	8.6e-05	0.000489	CcSEcCtD
Trametinib—Dermatitis—Irinotecan—pancreatic cancer	8.59e-05	0.000488	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	8.59e-05	0.000488	CcSEcCtD
Trametinib—Headache—Irinotecan—pancreatic cancer	8.54e-05	0.000486	CcSEcCtD
Trametinib—Insomnia—Docetaxel—pancreatic cancer	8.53e-05	0.000485	CcSEcCtD
Trametinib—Vomiting—Gemcitabine—pancreatic cancer	8.45e-05	0.00048	CcSEcCtD
Trametinib—Bradycardia—Doxorubicin—pancreatic cancer	8.43e-05	0.000479	CcSEcCtD
Trametinib—Rash—Gemcitabine—pancreatic cancer	8.38e-05	0.000476	CcSEcCtD
Trametinib—Dermatitis—Gemcitabine—pancreatic cancer	8.37e-05	0.000476	CcSEcCtD
Trametinib—Eye disorder—Epirubicin—pancreatic cancer	8.36e-05	0.000476	CcSEcCtD
Trametinib—Haemoglobin—Doxorubicin—pancreatic cancer	8.32e-05	0.000473	CcSEcCtD
Trametinib—Headache—Gemcitabine—pancreatic cancer	8.32e-05	0.000473	CcSEcCtD
Trametinib—Cardiac disorder—Epirubicin—pancreatic cancer	8.31e-05	0.000472	CcSEcCtD
Trametinib—Vomiting—Fluorouracil—pancreatic cancer	8.3e-05	0.000472	CcSEcCtD
Trametinib—Haemorrhage—Doxorubicin—pancreatic cancer	8.28e-05	0.000471	CcSEcCtD
Trametinib—Rash—Fluorouracil—pancreatic cancer	8.23e-05	0.000468	CcSEcCtD
Trametinib—Dermatitis—Fluorouracil—pancreatic cancer	8.23e-05	0.000468	CcSEcCtD
Trametinib—Decreased appetite—Docetaxel—pancreatic cancer	8.19e-05	0.000466	CcSEcCtD
Trametinib—Headache—Fluorouracil—pancreatic cancer	8.18e-05	0.000465	CcSEcCtD
Trametinib—Urinary tract disorder—Doxorubicin—pancreatic cancer	8.18e-05	0.000465	CcSEcCtD
Trametinib—Oedema peripheral—Doxorubicin—pancreatic cancer	8.16e-05	0.000464	CcSEcCtD
Trametinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	8.14e-05	0.000463	CcSEcCtD
Trametinib—Connective tissue disorder—Doxorubicin—pancreatic cancer	8.14e-05	0.000463	CcSEcCtD
Trametinib—Fatigue—Docetaxel—pancreatic cancer	8.13e-05	0.000462	CcSEcCtD
Trametinib—Angiopathy—Epirubicin—pancreatic cancer	8.12e-05	0.000462	CcSEcCtD
Trametinib—Urethral disorder—Doxorubicin—pancreatic cancer	8.12e-05	0.000462	CcSEcCtD
Trametinib—Nausea—Irinotecan—pancreatic cancer	8.1e-05	0.000461	CcSEcCtD
Trametinib—Mediastinal disorder—Epirubicin—pancreatic cancer	8.07e-05	0.000459	CcSEcCtD
Trametinib—Constipation—Docetaxel—pancreatic cancer	8.06e-05	0.000458	CcSEcCtD
Trametinib—Chills—Epirubicin—pancreatic cancer	8.03e-05	0.000457	CcSEcCtD
Trametinib—Arrhythmia—Epirubicin—pancreatic cancer	7.99e-05	0.000455	CcSEcCtD
Trametinib—Nausea—Gemcitabine—pancreatic cancer	7.89e-05	0.000449	CcSEcCtD
Trametinib—Mental disorder—Epirubicin—pancreatic cancer	7.84e-05	0.000446	CcSEcCtD
Trametinib—Malnutrition—Epirubicin—pancreatic cancer	7.79e-05	0.000443	CcSEcCtD
Trametinib—Erythema—Epirubicin—pancreatic cancer	7.79e-05	0.000443	CcSEcCtD
Trametinib—Nausea—Fluorouracil—pancreatic cancer	7.76e-05	0.000441	CcSEcCtD
Trametinib—Eye disorder—Doxorubicin—pancreatic cancer	7.74e-05	0.00044	CcSEcCtD
Trametinib—Gastrointestinal pain—Docetaxel—pancreatic cancer	7.71e-05	0.000438	CcSEcCtD
Trametinib—Cardiac disorder—Doxorubicin—pancreatic cancer	7.69e-05	0.000437	CcSEcCtD
Trametinib—Dysgeusia—Epirubicin—pancreatic cancer	7.63e-05	0.000434	CcSEcCtD
Trametinib—Back pain—Epirubicin—pancreatic cancer	7.54e-05	0.000428	CcSEcCtD
Trametinib—Angiopathy—Doxorubicin—pancreatic cancer	7.51e-05	0.000427	CcSEcCtD
Trametinib—Muscle spasms—Epirubicin—pancreatic cancer	7.49e-05	0.000426	CcSEcCtD
Trametinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	7.46e-05	0.000424	CcSEcCtD
Trametinib—Abdominal pain—Docetaxel—pancreatic cancer	7.45e-05	0.000424	CcSEcCtD
Trametinib—Body temperature increased—Docetaxel—pancreatic cancer	7.45e-05	0.000424	CcSEcCtD
Trametinib—Chills—Doxorubicin—pancreatic cancer	7.43e-05	0.000422	CcSEcCtD
Trametinib—Arrhythmia—Doxorubicin—pancreatic cancer	7.4e-05	0.000421	CcSEcCtD
Trametinib—Vision blurred—Epirubicin—pancreatic cancer	7.34e-05	0.000417	CcSEcCtD
Trametinib—Mental disorder—Doxorubicin—pancreatic cancer	7.25e-05	0.000412	CcSEcCtD
Trametinib—Malnutrition—Doxorubicin—pancreatic cancer	7.21e-05	0.00041	CcSEcCtD
Trametinib—Erythema—Doxorubicin—pancreatic cancer	7.21e-05	0.00041	CcSEcCtD
Trametinib—Anaemia—Epirubicin—pancreatic cancer	7.2e-05	0.000409	CcSEcCtD
Trametinib—Dysgeusia—Doxorubicin—pancreatic cancer	7.06e-05	0.000401	CcSEcCtD
Trametinib—Leukopenia—Epirubicin—pancreatic cancer	6.97e-05	0.000397	CcSEcCtD
Trametinib—Back pain—Doxorubicin—pancreatic cancer	6.97e-05	0.000396	CcSEcCtD
Trametinib—Muscle spasms—Doxorubicin—pancreatic cancer	6.93e-05	0.000394	CcSEcCtD
Trametinib—Cough—Epirubicin—pancreatic cancer	6.8e-05	0.000387	CcSEcCtD
Trametinib—Vision blurred—Doxorubicin—pancreatic cancer	6.79e-05	0.000386	CcSEcCtD
Trametinib—Asthenia—Docetaxel—pancreatic cancer	6.76e-05	0.000385	CcSEcCtD
Trametinib—Hypertension—Epirubicin—pancreatic cancer	6.73e-05	0.000382	CcSEcCtD
Trametinib—Pruritus—Docetaxel—pancreatic cancer	6.67e-05	0.000379	CcSEcCtD
Trametinib—Anaemia—Doxorubicin—pancreatic cancer	6.66e-05	0.000379	CcSEcCtD
Trametinib—Arthralgia—Epirubicin—pancreatic cancer	6.63e-05	0.000377	CcSEcCtD
Trametinib—Myalgia—Epirubicin—pancreatic cancer	6.63e-05	0.000377	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	6.59e-05	0.000375	CcSEcCtD
Trametinib—Dry mouth—Epirubicin—pancreatic cancer	6.49e-05	0.000369	CcSEcCtD
Trametinib—Leukopenia—Doxorubicin—pancreatic cancer	6.45e-05	0.000367	CcSEcCtD
Trametinib—Diarrhoea—Docetaxel—pancreatic cancer	6.45e-05	0.000367	CcSEcCtD
Trametinib—Oedema—Epirubicin—pancreatic cancer	6.36e-05	0.000362	CcSEcCtD
Trametinib—Infection—Epirubicin—pancreatic cancer	6.32e-05	0.000359	CcSEcCtD
Trametinib—Cough—Doxorubicin—pancreatic cancer	6.29e-05	0.000358	CcSEcCtD
Trametinib—Nervous system disorder—Epirubicin—pancreatic cancer	6.24e-05	0.000355	CcSEcCtD
Trametinib—Dizziness—Docetaxel—pancreatic cancer	6.23e-05	0.000354	CcSEcCtD
Trametinib—Thrombocytopenia—Epirubicin—pancreatic cancer	6.23e-05	0.000354	CcSEcCtD
Trametinib—Hypertension—Doxorubicin—pancreatic cancer	6.22e-05	0.000354	CcSEcCtD
Trametinib—Skin disorder—Epirubicin—pancreatic cancer	6.18e-05	0.000351	CcSEcCtD
Trametinib—Hyperhidrosis—Epirubicin—pancreatic cancer	6.15e-05	0.000349	CcSEcCtD
Trametinib—Arthralgia—Doxorubicin—pancreatic cancer	6.14e-05	0.000349	CcSEcCtD
Trametinib—Myalgia—Doxorubicin—pancreatic cancer	6.14e-05	0.000349	CcSEcCtD
Trametinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	6.09e-05	0.000347	CcSEcCtD
Trametinib—Dry mouth—Doxorubicin—pancreatic cancer	6e-05	0.000341	CcSEcCtD
Trametinib—Vomiting—Docetaxel—pancreatic cancer	5.99e-05	0.000341	CcSEcCtD
Trametinib—Rash—Docetaxel—pancreatic cancer	5.94e-05	0.000338	CcSEcCtD
Trametinib—Dermatitis—Docetaxel—pancreatic cancer	5.94e-05	0.000338	CcSEcCtD
Trametinib—Headache—Docetaxel—pancreatic cancer	5.91e-05	0.000336	CcSEcCtD
Trametinib—Oedema—Doxorubicin—pancreatic cancer	5.88e-05	0.000335	CcSEcCtD
Trametinib—Infection—Doxorubicin—pancreatic cancer	5.84e-05	0.000332	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	5.79e-05	0.000329	CcSEcCtD
Trametinib—Nervous system disorder—Doxorubicin—pancreatic cancer	5.77e-05	0.000328	CcSEcCtD
Trametinib—Thrombocytopenia—Doxorubicin—pancreatic cancer	5.76e-05	0.000328	CcSEcCtD
Trametinib—Insomnia—Epirubicin—pancreatic cancer	5.75e-05	0.000327	CcSEcCtD
Trametinib—Skin disorder—Doxorubicin—pancreatic cancer	5.71e-05	0.000325	CcSEcCtD
Trametinib—Hyperhidrosis—Doxorubicin—pancreatic cancer	5.69e-05	0.000323	CcSEcCtD
Trametinib—Nausea—Docetaxel—pancreatic cancer	5.6e-05	0.000318	CcSEcCtD
Trametinib—Decreased appetite—Epirubicin—pancreatic cancer	5.53e-05	0.000314	CcSEcCtD
Trametinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	5.49e-05	0.000312	CcSEcCtD
Trametinib—Fatigue—Epirubicin—pancreatic cancer	5.48e-05	0.000312	CcSEcCtD
Trametinib—Constipation—Epirubicin—pancreatic cancer	5.44e-05	0.000309	CcSEcCtD
Trametinib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	5.36e-05	0.000305	CcSEcCtD
Trametinib—Insomnia—Doxorubicin—pancreatic cancer	5.32e-05	0.000303	CcSEcCtD
Trametinib—Gastrointestinal pain—Epirubicin—pancreatic cancer	5.2e-05	0.000296	CcSEcCtD
Trametinib—Decreased appetite—Doxorubicin—pancreatic cancer	5.11e-05	0.000291	CcSEcCtD
Trametinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	5.08e-05	0.000289	CcSEcCtD
Trametinib—Fatigue—Doxorubicin—pancreatic cancer	5.07e-05	0.000288	CcSEcCtD
Trametinib—Constipation—Doxorubicin—pancreatic cancer	5.03e-05	0.000286	CcSEcCtD
Trametinib—Abdominal pain—Epirubicin—pancreatic cancer	5.03e-05	0.000286	CcSEcCtD
Trametinib—Body temperature increased—Epirubicin—pancreatic cancer	5.03e-05	0.000286	CcSEcCtD
Trametinib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	4.81e-05	0.000274	CcSEcCtD
Trametinib—Abdominal pain—Doxorubicin—pancreatic cancer	4.65e-05	0.000264	CcSEcCtD
Trametinib—Body temperature increased—Doxorubicin—pancreatic cancer	4.65e-05	0.000264	CcSEcCtD
Trametinib—Asthenia—Epirubicin—pancreatic cancer	4.56e-05	0.000259	CcSEcCtD
Trametinib—Pruritus—Epirubicin—pancreatic cancer	4.5e-05	0.000256	CcSEcCtD
Trametinib—Diarrhoea—Epirubicin—pancreatic cancer	4.35e-05	0.000247	CcSEcCtD
Trametinib—Asthenia—Doxorubicin—pancreatic cancer	4.22e-05	0.00024	CcSEcCtD
Trametinib—Dizziness—Epirubicin—pancreatic cancer	4.2e-05	0.000239	CcSEcCtD
Trametinib—Pruritus—Doxorubicin—pancreatic cancer	4.16e-05	0.000237	CcSEcCtD
Trametinib—Vomiting—Epirubicin—pancreatic cancer	4.04e-05	0.00023	CcSEcCtD
Trametinib—Diarrhoea—Doxorubicin—pancreatic cancer	4.03e-05	0.000229	CcSEcCtD
Trametinib—Rash—Epirubicin—pancreatic cancer	4.01e-05	0.000228	CcSEcCtD
Trametinib—Dermatitis—Epirubicin—pancreatic cancer	4.01e-05	0.000228	CcSEcCtD
Trametinib—Headache—Epirubicin—pancreatic cancer	3.98e-05	0.000226	CcSEcCtD
Trametinib—Dizziness—Doxorubicin—pancreatic cancer	3.89e-05	0.000221	CcSEcCtD
Trametinib—Nausea—Epirubicin—pancreatic cancer	3.78e-05	0.000215	CcSEcCtD
Trametinib—Vomiting—Doxorubicin—pancreatic cancer	3.74e-05	0.000213	CcSEcCtD
Trametinib—Rash—Doxorubicin—pancreatic cancer	3.71e-05	0.000211	CcSEcCtD
Trametinib—Dermatitis—Doxorubicin—pancreatic cancer	3.71e-05	0.000211	CcSEcCtD
Trametinib—Headache—Doxorubicin—pancreatic cancer	3.69e-05	0.00021	CcSEcCtD
Trametinib—Nausea—Doxorubicin—pancreatic cancer	3.49e-05	0.000199	CcSEcCtD
Trametinib—MAP2K2—Signaling by NGF—AKT1—pancreatic cancer	1.65e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—NRAS—pancreatic cancer	1.65e-05	0.000105	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SST—pancreatic cancer	1.64e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—BCL2L1—pancreatic cancer	1.63e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PTEN—pancreatic cancer	1.63e-05	0.000104	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—TSC2—pancreatic cancer	1.62e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CNR1—pancreatic cancer	1.62e-05	0.000103	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—JAG1—pancreatic cancer	1.6e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—SRC—pancreatic cancer	1.6e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH3—pancreatic cancer	1.6e-05	0.000102	CbGpPWpGaD
Trametinib—MAP2K1—Axon guidance—HRAS—pancreatic cancer	1.58e-05	0.0001	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TYMP—pancreatic cancer	1.57e-05	0.0001	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TERT—pancreatic cancer	1.57e-05	9.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CG—pancreatic cancer	1.57e-05	9.98e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—CTNNB1—pancreatic cancer	1.56e-05	9.95e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—GCG—pancreatic cancer	1.56e-05	9.93e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—VEGFA—pancreatic cancer	1.56e-05	9.91e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—STAT3—pancreatic cancer	1.54e-05	9.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by NGF—AKT1—pancreatic cancer	1.54e-05	9.79e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—NRAS—pancreatic cancer	1.54e-05	9.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TGFB1—pancreatic cancer	1.53e-05	9.73e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—BCL2L1—pancreatic cancer	1.53e-05	9.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PTEN—pancreatic cancer	1.53e-05	9.69e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—TSC2—pancreatic cancer	1.52e-05	9.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CNR1—pancreatic cancer	1.51e-05	9.62e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—SRC—pancreatic cancer	1.51e-05	9.61e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HIF1A—pancreatic cancer	1.5e-05	9.55e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—EGFR—pancreatic cancer	1.5e-05	9.54e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TSC2—pancreatic cancer	1.5e-05	9.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AGTR1—pancreatic cancer	1.49e-05	9.47e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NFKBIA—pancreatic cancer	1.48e-05	9.41e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TERT—pancreatic cancer	1.47e-05	9.34e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STK11—pancreatic cancer	1.47e-05	9.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CG—pancreatic cancer	1.47e-05	9.33e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—APOE—pancreatic cancer	1.47e-05	9.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—GCG—pancreatic cancer	1.46e-05	9.29e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—NRAS—pancreatic cancer	1.45e-05	9.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TGFB1—pancreatic cancer	1.43e-05	9.1e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—TNF—pancreatic cancer	1.43e-05	9.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGF—pancreatic cancer	1.42e-05	9.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—KRAS—pancreatic cancer	1.42e-05	9.01e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—SRC—pancreatic cancer	1.41e-05	8.99e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HIF1A—pancreatic cancer	1.41e-05	8.94e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—EGFR—pancreatic cancer	1.4e-05	8.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TSC2—pancreatic cancer	1.4e-05	8.91e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AGTR1—pancreatic cancer	1.39e-05	8.86e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NFKBIA—pancreatic cancer	1.39e-05	8.8e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CD—pancreatic cancer	1.38e-05	8.77e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STK11—pancreatic cancer	1.37e-05	8.73e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—APOE—pancreatic cancer	1.37e-05	8.72e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—NRAS—pancreatic cancer	1.36e-05	8.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NOTCH1—pancreatic cancer	1.35e-05	8.6e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—TNF—pancreatic cancer	1.34e-05	8.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGF—pancreatic cancer	1.33e-05	8.43e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—KRAS—pancreatic cancer	1.33e-05	8.43e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—EGFR—pancreatic cancer	1.33e-05	8.42e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CDH1—pancreatic cancer	1.32e-05	8.39e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGF—pancreatic cancer	1.31e-05	8.32e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.3e-05	8.25e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CD—pancreatic cancer	1.29e-05	8.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SMAD4—pancreatic cancer	1.29e-05	8.17e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GLP1R—pancreatic cancer	1.27e-05	8.06e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NOTCH1—pancreatic cancer	1.27e-05	8.05e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CD—pancreatic cancer	1.26e-05	8.01e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HES1—pancreatic cancer	1.26e-05	7.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—KRAS—pancreatic cancer	1.25e-05	7.96e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—DPYD—pancreatic cancer	1.25e-05	7.93e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—EGFR—pancreatic cancer	1.24e-05	7.88e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CDH1—pancreatic cancer	1.23e-05	7.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGF—pancreatic cancer	1.22e-05	7.78e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—HRAS—pancreatic cancer	1.2e-05	7.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SMAD4—pancreatic cancer	1.2e-05	7.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CB—pancreatic cancer	1.2e-05	7.64e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—SLC2A2—pancreatic cancer	1.18e-05	7.53e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CD—pancreatic cancer	1.18e-05	7.5e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HES1—pancreatic cancer	1.17e-05	7.47e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.17e-05	7.45e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—KRAS—pancreatic cancer	1.17e-05	7.44e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CD—pancreatic cancer	1.16e-05	7.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—CXCL8—pancreatic cancer	1.16e-05	7.35e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—PIK3CA—pancreatic cancer	1.15e-05	7.31e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.13e-05	7.19e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—HRAS—pancreatic cancer	1.13e-05	7.16e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CB—pancreatic cancer	1.13e-05	7.15e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PRSS1—pancreatic cancer	1.11e-05	7.09e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TERT—pancreatic cancer	1.1e-05	6.99e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CB—pancreatic cancer	1.1e-05	6.98e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CD—pancreatic cancer	1.09e-05	6.92e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—CXCL8—pancreatic cancer	1.08e-05	6.87e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—PIK3CA—pancreatic cancer	1.08e-05	6.84e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—HRAS—pancreatic cancer	1.06e-05	6.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Developmental Biology—AKT1—pancreatic cancer	1.06e-05	6.76e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HIF1A—pancreatic cancer	1.05e-05	6.69e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TSC2—pancreatic cancer	1.05e-05	6.67e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.03e-05	6.55e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TERT—pancreatic cancer	1.03e-05	6.54e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CB—pancreatic cancer	1.03e-05	6.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—APOE—pancreatic cancer	1.03e-05	6.53e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CB—pancreatic cancer	1.01e-05	6.45e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KDR—pancreatic cancer	1.01e-05	6.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTGS2—pancreatic cancer	1.01e-05	6.39e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—HRAS—pancreatic cancer	9.96e-06	6.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Developmental Biology—AKT1—pancreatic cancer	9.95e-06	6.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HIF1A—pancreatic cancer	9.85e-06	6.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TSC2—pancreatic cancer	9.82e-06	6.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—CTNNB1—pancreatic cancer	9.74e-06	6.19e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—ARG2—pancreatic cancer	9.67e-06	6.14e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—APOE—pancreatic cancer	9.61e-06	6.11e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NFKBIA—pancreatic cancer	9.57e-06	6.08e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PTEN—pancreatic cancer	9.5e-06	6.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CB—pancreatic cancer	9.49e-06	6.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NOTCH1—pancreatic cancer	9.48e-06	6.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KDR—pancreatic cancer	9.42e-06	5.98e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTGS2—pancreatic cancer	9.4e-06	5.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Innate Immune System—AKT1—pancreatic cancer	9.4e-06	5.97e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CG—pancreatic cancer	9.27e-06	5.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—NRAS—pancreatic cancer	9.27e-06	5.89e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—CD44—pancreatic cancer	9.17e-06	5.83e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGF—pancreatic cancer	9.16e-06	5.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—CTNNB1—pancreatic cancer	9.11e-06	5.79e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—CTNNB1—pancreatic cancer	8.99e-06	5.72e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	8.98e-06	5.71e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NFKBIA—pancreatic cancer	8.96e-06	5.69e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	8.9e-06	5.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PTEN—pancreatic cancer	8.88e-06	5.65e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NOTCH1—pancreatic cancer	8.87e-06	5.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—SRC—pancreatic cancer	8.81e-06	5.6e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—GCG—pancreatic cancer	8.79e-06	5.59e-05	CbGpPWpGaD
Trametinib—MAP2K1—Innate Immune System—AKT1—pancreatic cancer	8.79e-06	5.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PTEN—pancreatic cancer	8.77e-06	5.57e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CG—pancreatic cancer	8.67e-06	5.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—NRAS—pancreatic cancer	8.67e-06	5.51e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGF—pancreatic cancer	8.57e-06	5.45e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—STAT3—pancreatic cancer	8.49e-06	5.4e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—NRAS—pancreatic cancer	8.47e-06	5.38e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TYMP—pancreatic cancer	8.45e-06	5.37e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—EGFR—pancreatic cancer	8.45e-06	5.37e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—CTNNB1—pancreatic cancer	8.42e-06	5.35e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—STK11—pancreatic cancer	8.27e-06	5.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—SRC—pancreatic cancer	8.24e-06	5.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PTEN—pancreatic cancer	8.2e-06	5.21e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CD—pancreatic cancer	8.15e-06	5.18e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—SRC—pancreatic cancer	8.13e-06	5.17e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—KRAS—pancreatic cancer	7.98e-06	5.07e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—STAT3—pancreatic cancer	7.95e-06	5.05e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—NRAS—pancreatic cancer	7.93e-06	5.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—EGFR—pancreatic cancer	7.9e-06	5.02e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—STAT3—pancreatic cancer	7.84e-06	4.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—NRAS—pancreatic cancer	7.82e-06	4.97e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	7.76e-06	4.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—EGFR—pancreatic cancer	7.72e-06	4.91e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CD—pancreatic cancer	7.63e-06	4.85e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—SRC—pancreatic cancer	7.61e-06	4.83e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—KRAS—pancreatic cancer	7.47e-06	4.74e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—STAT3—pancreatic cancer	7.34e-06	4.66e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—PIK3CA—pancreatic cancer	7.33e-06	4.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—NRAS—pancreatic cancer	7.32e-06	4.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—KRAS—pancreatic cancer	7.29e-06	4.63e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—MYC—pancreatic cancer	7.29e-06	4.63e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—TGFB1—pancreatic cancer	7.27e-06	4.62e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—EGFR—pancreatic cancer	7.22e-06	4.59e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—EGFR—pancreatic cancer	7.13e-06	4.53e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—TYMS—pancreatic cancer	7.11e-06	4.52e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CB—pancreatic cancer	7.1e-06	4.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—PIK3CA—pancreatic cancer	6.86e-06	4.36e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CXCL8—pancreatic cancer	6.83e-06	4.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—KRAS—pancreatic cancer	6.82e-06	4.34e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—MYC—pancreatic cancer	6.82e-06	4.33e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	6.81e-06	4.33e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—TGFB1—pancreatic cancer	6.8e-06	4.32e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—HRAS—pancreatic cancer	6.78e-06	4.31e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—KRAS—pancreatic cancer	6.73e-06	4.28e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—DPYD—pancreatic cancer	6.7e-06	4.26e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—PIK3CA—pancreatic cancer	6.7e-06	4.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—EGFR—pancreatic cancer	6.67e-06	4.24e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CB—pancreatic cancer	6.65e-06	4.22e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CASP3—pancreatic cancer	6.53e-06	4.15e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CXCL8—pancreatic cancer	6.39e-06	4.06e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CCND1—pancreatic cancer	6.36e-06	4.04e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	6.36e-06	4.04e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—HRAS—pancreatic cancer	6.35e-06	4.03e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—CTNNB1—pancreatic cancer	6.3e-06	4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—KRAS—pancreatic cancer	6.3e-06	4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—PIK3CA—pancreatic cancer	6.27e-06	3.98e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—HRAS—pancreatic cancer	6.2e-06	3.94e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—PIK3CA—pancreatic cancer	6.18e-06	3.93e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MMP9—pancreatic cancer	6.18e-06	3.92e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PTEN—pancreatic cancer	6.14e-06	3.9e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CASP3—pancreatic cancer	6.11e-06	3.89e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling by GPCR—AKT1—pancreatic cancer	5.99e-06	3.81e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CCND1—pancreatic cancer	5.95e-06	3.78e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—CTNNB1—pancreatic cancer	5.89e-06	3.75e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—HRAS—pancreatic cancer	5.8e-06	3.69e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—PIK3CA—pancreatic cancer	5.79e-06	3.68e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—APOE—pancreatic cancer	5.78e-06	3.68e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MMP9—pancreatic cancer	5.78e-06	3.67e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PTEN—pancreatic cancer	5.74e-06	3.65e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—HRAS—pancreatic cancer	5.72e-06	3.64e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—SRC—pancreatic cancer	5.69e-06	3.62e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling by GPCR—AKT1—pancreatic cancer	5.6e-06	3.56e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—VEGFA—pancreatic cancer	5.54e-06	3.52e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—STAT3—pancreatic cancer	5.49e-06	3.49e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—NRAS—pancreatic cancer	5.48e-06	3.48e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	5.48e-06	3.48e-05	CbGpPWpGaD
Trametinib—MAP2K2—Immune System—AKT1—pancreatic cancer	5.47e-06	3.48e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—HRAS—pancreatic cancer	5.35e-06	3.4e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—SRC—pancreatic cancer	5.33e-06	3.39e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	5.22e-06	3.32e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—VEGFA—pancreatic cancer	5.19e-06	3.3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—STAT3—pancreatic cancer	5.14e-06	3.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—NRAS—pancreatic cancer	5.12e-06	3.26e-05	CbGpPWpGaD
Trametinib—MAP2K1—Immune System—AKT1—pancreatic cancer	5.12e-06	3.25e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—MYC—pancreatic cancer	5.1e-06	3.24e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TGFB1—pancreatic cancer	5.09e-06	3.23e-05	CbGpPWpGaD
Trametinib—MAP2K2—Disease—AKT1—pancreatic cancer	5.05e-06	3.21e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PPARG—pancreatic cancer	5.04e-06	3.2e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—EGFR—pancreatic cancer	4.99e-06	3.17e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—CD44—pancreatic cancer	4.92e-06	3.13e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—MYC—pancreatic cancer	4.77e-06	3.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TGFB1—pancreatic cancer	4.76e-06	3.03e-05	CbGpPWpGaD
Trametinib—MAP2K1—Disease—AKT1—pancreatic cancer	4.73e-06	3e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—GCG—pancreatic cancer	4.72e-06	3e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—KRAS—pancreatic cancer	4.71e-06	3e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—EGFR—pancreatic cancer	4.67e-06	2.97e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	4.59e-06	2.92e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—STK11—pancreatic cancer	4.44e-06	2.82e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—KRAS—pancreatic cancer	4.41e-06	2.8e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—PIK3CA—pancreatic cancer	4.33e-06	2.75e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—TP53—pancreatic cancer	4.19e-06	2.66e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—PIK3CA—pancreatic cancer	4.05e-06	2.58e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—HRAS—pancreatic cancer	4.01e-06	2.55e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	4e-06	2.54e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTGS2—pancreatic cancer	3.96e-06	2.52e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—TP53—pancreatic cancer	3.92e-06	2.49e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	3.82e-06	2.43e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—HRAS—pancreatic cancer	3.75e-06	2.38e-05	CbGpPWpGaD
Trametinib—MAP2K2—Signaling Pathways—AKT1—pancreatic cancer	3.54e-06	2.25e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PTEN—pancreatic cancer	3.46e-06	2.2e-05	CbGpPWpGaD
Trametinib—MAP2K1—Signaling Pathways—AKT1—pancreatic cancer	3.31e-06	2.1e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—APOE—pancreatic cancer	3.1e-06	1.97e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	2.8e-06	1.78e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	2.7e-06	1.72e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.46e-06	1.57e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	2.44e-06	1.55e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.15e-06	1.36e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.13e-06	1.35e-05	CbGpPWpGaD
Trametinib—CYP2C8—Metabolism—AKT1—pancreatic cancer	1.99e-06	1.27e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.86e-06	1.18e-05	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.31e-06	8.32e-06	CbGpPWpGaD
Trametinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.07e-06	6.8e-06	CbGpPWpGaD
